Background: Clostridioides difficile infection (CDI) is a common, often nosocomial infection associated with substantial morbidity and mortality. Antibiotics are the most important modifiable risk factor, but empiric antibiotics remain appropriate for many patients with severe acute illness. Which antibiotics minimize the risk of CDI remains an important unanswered question. Because protective equipment and isolation were [...]

Background: Microbiota-based treatments have shown promise to reduce recurrence for recurrent Clostridioides difficile infections (rCDI), but consistent and reliable safety data are needed to support regulatory approvals and broaden patient access. Here we provide cumulative safety data from 5 prospective clinical studies evaluating RBX2660—a standardized, microbiota-based investigational live biotherapeutic—for reducing rCDI. Methods: This analysis included [...]

Background: Recurrent Clostridioides difficile infection (rCDI) is an urgent public health threat. RBX2660 is a standardized, stabilized, investigational microbiota-based live biotherapeutic that has been evaluated in 5 prospective clinical trials. Eligibility criteria in clinical trials are often narrowly defined, excluding broader patient populations. Herein, we report a retrospective analysis of safety and efficacy of RBX2660 [...]

Background: Clostridioides difficile infection (CDI) is a leading healthcare-associated infection causing debilitating diarrhea, life-threatening complications, 20,500 deaths and healthcare costs of up to $5.4 billion annually in the US. The main driver of CDI costs is hospitalizations, and patients with higher CDI recurrence rates have more hospitalizations and emergency department visits and longer hospital stays. [...]

Background: Clostridioides difficile infection (CDI) is a common, often nosocomial infection associated with substantial morbidity and mortality. Antibiotics are the most important modifiable risk factor, but empiric antibiotics remain appropriate for many patients with severe acute illness. Which antibiotics minimize the risk of CDI remains an important unanswered question. Because protective equipment and isolation were [...]